Core Viewpoint - The company plans to use idle raised funds amounting to 168 million yuan for cash management through financial products, aiming to enhance fund utilization efficiency and shareholder returns while ensuring that the main investment projects remain unaffected [1][2][3]. Investment Overview - **Investment Amount**: The total amount for the financial products is 168 million yuan [1][3]. - **Source of Funds**: The funds are sourced from temporarily idle raised funds from a non-public stock issuance, totaling approximately 2.2 billion yuan after deducting issuance costs [3][4]. - **Investment Purpose**: The cash management aims to maximize shareholder interests by improving the efficiency and returns of idle funds without impacting the main investment projects [2][8]. Investment Details - **Investment Types**: The company is investing in bank wealth management products, which are characterized as principal-protected and floating return products [5][6]. - **Investment Duration**: The investment periods for the financial products range from 47 to 60 days, with specific start and end dates for each product [6][8]. - **Expected Returns**: The expected annualized returns for the products vary, with some products offering rates around 0.6% to 2.4% [5][6]. Financial Impact - **Recent Financial Metrics**: As of June 30, 2025, the company's total assets were approximately 17.84 billion yuan, with a net asset value of about 3.1 billion yuan [8][9]. - **Debt Ratio**: The company's debt ratio stood at 78.41%, and the investment in financial products represents 5.25% of the company's cash holdings [9]. - **Effect on Operations**: The cash management initiative is not expected to adversely affect the company's main business operations or financial health, as it is designed to enhance fund efficiency while maintaining operational liquidity [8][9].

Core Viewpoint - The company, Shengda Biology, announced the use of idle raised funds for cash management, indicating a strategic move to enhance liquidity and yield on its financial resources [1] Group 1: Financial Management - Shengda Biology and its subsidiaries will utilize up to RMB 23,000.00 million of temporarily idle raised funds for cash management [1] - The total amount for this cash management initiative is RMB 5,000.00 million, which will be invested in structured deposit products from the Bank of China [1] - The expected annualized yield for the investment ranges from 0.60% to 1.80%, with a product duration of 32 days [1]